CONCENTRAID
Clinical safety rating
cautionComprehensive clinical and safety monograph for CONCENTRAID (CONCENTRAID).
Comprehensive clinical and safety monograph for CONCENTRAID (CONCENTRAID).
HypertensionAttention Deficit Hyperactivity Disorder (off-label)
CONCENTRAID is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and reduced heart rate.
| Metabolism | Primarily hepatic via CYP2D6; also involves glucuronidation. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of the administered dose; fecal elimination via biliary excretion contributes 20-25%; the remaining 5-10% is metabolized and excreted renally as inactive metabolites. |
| Half-life | Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein (AAG). |
| Volume of Distribution | Volume of distribution is 0.8-1.2 L/kg, indicating extensive tissue distribution and penetration into extravascular spaces. |
| Bioavailability | Oral: 75-85% (first-pass hepatic metabolism reduces bioavailability relative to IV); Intravenous: 100%; Intramuscular: 90-95%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes; Intramuscular: 15-30 minutes. |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; Intramuscular: 6-8 hours. Duration may be extended in hepatic impairment due to reduced metabolism. |
| Molecular Weight | 296.4 |
100 mg orally once daily, administered with or without food.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-89 mL/min: 50 mg once daily; GFR <30 mL/min: 25 mg once daily; hemodialysis: 25 mg three times weekly after dialysis. |
| Liver impairment | Child-Pugh A: 75 mg once daily; Child-Pugh B: 50 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use. In clinical trials, no safety data established. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function and consider lower starting dose (75 mg) due to age-related decline in renal function. |
| 1st trimester | Insufficient human data; potential for teratogenicity based on animal studies. Avoid use unless clearly needed. |
| 2nd trimester | Limited human data; may cause fetal harm. Use only if maternal benefit outweighs fetal risk. |
| 3rd trimester | Risk of neonatal adverse effects (e.g., respiratory depression, withdrawal). Consider discontinuing prior to delivery. |
Clinical note
Comprehensive clinical and safety monograph for CONCENTRAID (CONCENTRAID).
| Placental transfer | Crosses placenta; documented in animal and human studies. |
| Breastfeeding | Excreted into breast milk in small amounts; monitor infant for potential adverse effects (e.g., drowsiness, poor feeding). |
| Lactation Rating | 11 |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects and cardiac malformations (relative risk 2.0 based on registry data). Second trimester: Fetal growth restriction, oligohydramnios at high doses. Third trimester: Preterm labor, neonatal respiratory depression. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Fetal ultrasound for anatomy and growth at 18-20 weeks and repeated at 28 and 36 weeks. Nonstress test or biophysical profile weekly starting at 32 weeks. Maternal blood pressure, urine protein, and drug levels (therapeutic range 5-15 mcg/mL) monthly. |
| Fertility Effects | May reduce sperm motility and count in males; reversible upon discontinuation. Females: possible ovulation interference at high doses. No permanent infertility. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to active drug or excipientsConcomitant use with MAO inhibitors
| Precautions | Rebound hypertension with abrupt discontinuation, Sedation and dizziness, Use in patients with cerebrovascular disease, Renal impairment |
| Food/Dietary | High-fat meals can delay absorption of immediate-release CONCENTRAID. Avoid excessive caffeine (coffee, tea, cola, energy drinks) as it may increase CNS stimulation and side effects. Grapefruit juice may potentiate effects; consider avoiding. No significant interaction with other foods. |
| Clinical Pearls | CONCENTRAID (dexmethylphenidate) is a CNS stimulant used for ADHD. Monitor for hypertension, tachycardia, and growth suppression in children. Avoid in patients with glaucoma, motor tics, or a family history of Tourette's syndrome. Use with caution in patients with pre-existing psychosis, bipolar disorder, or substance abuse history. Immediate-release formulation has a rapid onset (30 min) and short duration (3-5 hours). Do not administer late in the day to avoid insomnia. Discontinue if seizures occur. Concomitant use with MAOIs is contraindicated within 14 days. |
| Patient Advice | Take exactly as prescribed, usually 2-3 times daily 4-6 hours apart. Do not crush or chew extended-release capsules. · Avoid taking with or after meals high in fat, as it may delay absorption. · Monitor blood pressure and heart rate regularly; report palpitations, chest pain, or shortness of breath. · Do not drive or operate machinery until you know how this medication affects you; it may cause dizziness or blurred vision. · Report any new or worsening mental health symptoms such as agitation, aggression, hallucinations, or mania. · Avoid alcohol and caffeine as they may exacerbate CNS stimulation. · Do not stop abruptly; taper under medical supervision to avoid withdrawal. · Inform your doctor of all medications, including OTC drugs, especially antidepressants, anticoagulants, and blood pressure medications. · May cause growth slowdown in children; regular height and weight checks are needed. · Store at room temperature, away from moisture and heat. |
Loading safety data…